

11th

& Breast - Gynecological Immunooncology International Cancer Conference



MAIN TOPICS

I - ONE WORLD AGAINST CANCER SESSION

II - De-escalating and Escalating Treatment

- Surgery
- Radiotherapy
- Systemic Therapy

III - Heterogeneity in Breast Cancer

- Intratumoral Heterogeneity and therapeutic implications of women with :

- HR positive tumor
- HER2 positive tumor
- Systemic therapies in BRCA +ve Breast Cancer-What's New?

- Significance of tumor infiltrating lymphocytes in patients with HER 2 +ve and TNBC.

- Liquid biopsies in Breast Cancer challenges and opportunities, any biomarker to assess late relapse?

- All patients diagnosed with MBC should undergo next generation sequencing?

- YES
- NO

- PI3K Inhibitors in Breast Cancer

- Gene expression signature should be used in Luminal node negative Breast Cancer?

- YES
- NO

- Pathology and genomics of lobular breast carcinomas and their precursors

- MULTIGENNE ASSAY VS KI67

IV - Hormonal Treatment

- Androgen receptor in breast cancer, when might it serve as suitable target?

- Is PR +ve tumors is real hormonal sensitive?

- Ovarian suppression, whom, which agents, how long and at what cost?

- Beyond Resistance of CD4/6 inhibitors. Clinical implications

V - Neoadjuvant setting

- Neoadjuvant in Luminal Premenopausal women. Indications for chemotherapy and tailored strategies

- Neoadjuvant in patients with HR+ve and Her2 -ve (Luminal) early Breast cancer

- Management of the axilla after neoadjuvant therapy: Beyond the clinical trials

VI - TNBC

- Molecular subtypes and clinical ramifications of TNBC

- PARP inhibitors and DNA damaging cytotoxic

- Neoadjuvant versus adjuvant approaches in early TNBC

VII - HER2 +VE Breast Cancer

- Can we improve treatment tailoring in advanced HER2 breast cancer?

- Early HER2 breast cancer. Doing more or less

- Advanced HER2 breast cancer. Overcoming treatment resistance.

- Lessons learned and opportunities from the neo-adjuvant setting

VIII - MBC

- Local therapy of limited disease in MBC, what is the evidence.

- Balancing active treatment and palliative care in MBC patients.

IX - Breast Cancer in special situations

- Pregnancy during breast cancer: any news?

- Sexual life after Breast Cancer

- Breast Cancer in Elderly

- Challenges in the management of locoregional recurrence

- Should all patients with locoregional recurrence receive systemic therapy?

- Multidisciplinary management of breast cancer brain metastasis.

X - Breast Cancer Prevention

- Preventing invasive breast cancer using endocrine therapy

- Risk communication and decision making in prevention of invasive breast cancer

XI - DCIS

- Postoperative Radiotherapy after DCIS: Useful for whom?

- Evaluation of margins in DCIS and Invasive Carcinoma: the pathologist perspective

- Estimating the magnitude of clinical benefit of local therapy in patients with DCIS

- Estimating the magnitude of clinical benefit of systemic therapy in patients with DCIS

XII- Clinical practice recommendation in management of NSCLC in collaboration with STIC (voting session)

XIII-Clinical practice recommendation in management of breast cancer in elderly in collaboration with SIOP (voting session)

XIV-Clinical practice recommendation in HER2 positive breast cancer (voting session)